|
Synonyms: AEVI-002 | AVTX-002 | CERC-002 | MDGN-002 | SAR-252067 | SAR252067 [3]
Compound class:
Antibody
Comment: Quisovalimab (AVTX-002) is a clinical stage, fully human IgG4 anti-LIGHT (TNFSF14) monoclonal antibody. It was developed for anti-inflammatory potential [3]. Quisovalimab binds to LIGHT and prevents it from interacting with its receptors on T cells [1].
As CERC-002, this agent was assessed for efficacy as a treament for COVID-19-related pneumonia and ARDS/acute lung injury, based on evidence of a pro-inflammatory effect of LIGHT on the interaction between T cells and airway smooth muscle cells [2]. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 12100 | quisovalimab |
| Synonyms |
|
| AEVI-002 | AVTX-002 | CERC-002 | MDGN-002 | SAR-252067 | SAR252067 [3] | |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1221 |
| Other databases | |
| GtoPdb PubChem SID | 458923809 |
| Search PubMed clinical trials | quisovalimab |
| Search PubMed titles | quisovalimab |
| Search PubMed titles/abstracts | quisovalimab |
